Preparation and Characterization of PLGA Microspheres Loaded by Cyclosporine-Cyclodextrin Complex Preparation of cyclosporine loaded microspheres
Iranian Journal of Pharmaceutical Sciences,
Vol. 1 Núm. 4 (2005),
1 October 2005
,
Página 195-201
https://doi.org/10.22037/ijps.v1.39537
Resumen
The purpose of this study was to prepare and characterize microspheres loaded by cyclosporine A(CyA)-cyclodextrin (CD) complex. To achieve this goal, PLGA microspheres loaded by CyA-CD complex were prepared by multiple emulsificationsolvent evaporation methods. Morphology, size, encapsulation efficiency and drug release from these microspheres were evaluated. Microscopic evaluation of
microspheres showed that microspheres were spherical in shape. The size analysis results indicated that size range varied from 1 to 50 mm for complex loaded microspheres. Encapsulation efficiency of microspheres was increased by increasing drug to polymer ratio. Drug release was found to be biphasic with a first more rapid release phase (burst) followed by a slower phase. After two weeks, 43.40%±3.45 of CyA was released from these microspheres. In conclusion, microspheres loaded with CyA-CD complex were prepared that could be used for control delivery of CyA.
- Cyclosporine A
- Cyclodextrin
- MicrospherePLGA
Cómo citar
Citas
[2] Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporine A in solid lipid nanoparticles. Int J Pharm 2002; 241: 341-4.
[3] Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of CyA-loaded poly (lactic acid)- poly(ethylene glycol) PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm 2001; 51: 111-8.
[4] Urata T, Nakano M, Arimori K. Modification of release rates of cyclosporine A from poly (Llactic acid) microspheres by fatty acid esters and in vivo evaluation of the microspheres. J Control Release 1999; 58:133-41.
[5] Lee E, Choi H, Lee S, Kim C. Bioavailability of cyclosporine Adispersed in sodium lauryl sulfate dextrin based solid microspheres. Int J Pharm 2001; 218: 125-31.
[6] Miyake K, Aroma H, Ire T, Hirayama F, Onekama K. Enhanced absorption of cyclosporine A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and non cannulated rats. Biol Pharm Bull 1999; 22: 66-72.
[7] Goo J, Chen Y, Ping Q. Pharmacokinetic behaviour of cyclosporine A in rabbits by oral administration of lecithin and sandimmune neoral. Int J Pharm 2001; 216: 17-21.
[ 8] Mueller EA, Kovaric JM. Improved dose linearity of cyclosporine formulation. Pharm Res1994; 11: 301-4.
[9] Ford J, Woolf J, Florence AT. Nanospheres of cyclosporine A: Poor oral absorption in dogs. Int J Pharm 1999; 183: 3-6.
[10] Carmen Varela M, Guzman M. Cyclosporineloaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur J Pharm Sci 2001; 12 :471-8.
[11] Passerini N, Craig DQM. Characterization of cyclosporine A loaded poly (D, L lactide- coglycolide) microspheres using modulated temperature differential scanning calorimetry. J Pharm Pharmacol 2002; 54: 913-9.
[12] Sanchez A, Vila-Jato JL, Alonso MJ. Development of biodegradable microspheres and nanospheres for controlled release of cyclosporine A. Int J Pharm 1993; 99: 263-73.
[13] Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke DR. In vitro evaluation of liposomal cyclosporine. Int J Pharm 1989; 57: 133-8.
[14] Fahr A, Seeling J. Liposomal formulation of cyclosporine A: a biophysical approach to pharmacokinetics and pharmacodynamics. Crit Rev Ther Drug Carrier Syst 2001; 18:141-72.
[15] Al-Angary AA, Bayomi MA, Khidr SH, Al- Meshal MA, Al-Dardiri M. Characterization, stability and in vivo t a rgeting of liposomal formulations containing cyclosporine. Int J Pharm 1995; 114: 221-5.
[16] Rosa G, Larobina D, Rotonda MI, Musto P, Quaglia F, Ungaro F. How cyclodextrin incorporation affects the properties of proteinloaded PLGA-based microspheres: the case of insulin/hydroxypropyl-β- cyclodextrin system. J Control Release 2005; 102: 71-83.
[17] Siepmann J, Faisant N, Akiki J, Richard J, Benoit J P. Effect of the size of biodegradable microparticles on drug release: Experiment and theory. J Control Release 2004; 96: 123-34.
[18] Jaifwal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high pressure emulsification solvent evaporation process. J Control Release 2004; 96: 169-78.
[19] Rodrigues JM, Melo K, Matos CE, Aguiar MMG, Silva A. The effect of cyclodextrins on the in vitro and in vivo properties of insulin loaded poly (D, L-lactic-co-glycolic acid) microsphere. Artificial Organs 2003; 27: 492-7.
[20] Hoyn S.H. Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med J 2000; 41: 720-34.
[21] Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-coglycolide) (PLGA) devices. Biomaterials 2000; 21: 2475-90.
[22] Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Sys 1995; 12: 1-99.
[23] Ran Y, Zhao L, Xu Q, Yalkowsky SH. Solubilization of cyclosporine A. AAPS Pharm Sci Tech 2001; 2: (www.aapspharmscitech.org).
[24] Lallemand F, Felt-Baeyens O, Besseghir K, Behar- Cohen F, Gurny R. Cyclosporine Adelivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 2003; 56: 307-18.
[25] Loftsson T, Magnudottir A, Masson M, Sigurjonsdottir JF. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 2002; 91: 2307-16.
[26] Loftsson T, Matthiasson K, Masson M. The effect of organic salts on cyclodextrin solubilization of drugs. Int J Pharm 2003; 262: 101-7.
[27] Stella VJ, Rao VM, Zannou EA, Zia V. Mechanism of drug release from cyclodextrin complexes. Adv Drug Deliver Rev 1999; 36: 3-16.
[28] Loftsson T, Frioriksdottir H. The effect of watersoluble polymer on the aqueous solubility and complexing abilities of β-cyclodextrin. Int J Pharm 1998; 163: 115-21.
[29] Filipovic-Grcic J, Voinovich D, Moneghini M, Becirevic-Lacan M, Magarotto L, Jalsenjak I. Chitosan microspheres with hydrocortisone and hydrocortisone hydroxypropyl-β- c y c l o d e x t r i n inclusion complex. Eur J Pharm Sci 2000; 9: 373-9.
[30] Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: Past, present and future. Nature Rev 2004; 3: 1023-35.
[31] Filipovic-Grcic J, Becirevic-Lacan M, Skalko N, Jalsenjak I. Chitosan microspheres of nifedipine and nifedipine-cyclodextrin inclusion complexes. Int J Pharm 1996; 135:183-90.
[32] Diwan M, Tafaghodi M, Sammuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 2002; 85: 247-62.
[33] Martin Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem 2004; 39: 1033- 46.
[34] Loftsson T, O’Fee R. Cyclodextrins in solid dosage forms. Business Brifing, Pharmatech 2003; 176-180.
[35] Malaekeh-Nikouie B, Sajadi Tabassi SA, Jaafari MR. Preparation and characterization of biodegradable microspheres encapsulated with cyclosporine A using different grades of PLGA. Iran J Basic Med Sci 2004; 7: 240-9.
[36] Jug M, Becirevic-Lacan M, Cetina-Cizmek B, Horvat M. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicamhydroxypropyl- beta-cyclodextrin inclusion complex. Pharmazie 2004; 59: 686-91.
- Resumen ##plugins.themes.ojsPlusA.frontend.article.viewed##: 63 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume 1_Issue 4_Pages 195-201 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 34 ##plugins.themes.ojsPlusA.frontend.article.times##